Clinical Trial Update: An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults [Phase 3]

View source ↗

Summary

Clinical trial update for a CHIKV VLP vaccine to prevent chikungunya infection in adolescents and adults. The Phase 3 study is currently NOT_YET_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chikungunya

Drugs mentioned

• CHIKV VLP Vaccine (Chikungunya virus-like particle vaccine)

Snippet

Sponsor: Bavarian Nordic | Conditions: Chikungunya Virus | Phase 3 | Status: NOT_YET_RECRUITING